Ole aofaʻi ole maketi o vailaʻau faʻamaʻi i le lalolagi atoa e tatau ona oʻo atu i le USD 50.02 piliona i le 2030 ma resitalaina se CAGR o le 3.4% i le vaitau o faʻataʻitaʻiga, e tusa ai ma lipoti lata mai a Lipoti ma Faʻamaumauga. O le atinaʻeina o vailaʻau fou, faʻaleleia, ma faʻafouina o se mea taua e faʻamoemoeina e faʻateleina ai tupe maua maketi i le vaitaimi o faʻataʻitaʻiga. Faʻateleina i le COVID-19 mataupu, faʻapea foʻi ma le faʻaauau pea ona maua o se paipa oloa malosi o vailaʻau faʻamaʻi, e faʻamoemoe e lagolago ai le tuputupu aʻe o tupe maua i le vaitau o faʻataʻitaʻiga. O auala o loʻo iai nei mo le atinaʻeina o vailaʻau faʻamaʻi, e pei o vailaʻau toe faʻaaogaina, ua maua le gauai, aʻo latou suʻesuʻeina auala fou mo le toe faʻaaogaina faʻatau pisinisi faʻamaonia pe teena vailaʻau sa iai muamua e togafitia ai faʻamaʻi pipisi o le manava. O filifiliga fa'alelei manuia mo fa'ama'i pipisi, e pei ole COVID-19, Human Immunodeficiency Virus (HIV), ma le Human Coronavirus (HCoV), o lo'o aofia ai i le taimi nei se lua pe sili atu tu'ufa'atasiga o vaila'au, aua e mafai ona latou tolopoina le atina'eina o fualaau fa'asaina. O nei auala e mafai ona fesoasoani e foia le afaina i tulaga ogaoga, i se taimi talafeagai ma taugofie.

O le tuputupu aʻe o faʻamaʻi eseese e ono taofia ai le faʻatupulaia o tupe maua i maketi i le vaitau o faʻataʻitaʻiga. O siama e fesuisuiai vave i le aluga o taimi, ma faʻaitiitia ai le aoga o togafitiga faʻamaʻi masani, pe a le aoga. O le mea lea, o vailaʻau faʻamaʻi o loʻo galue faasaga i faʻamaʻi eseese o le manava e tatau ona atiaʻe i taimi uma ina ia puipuia ai faʻamaʻi faʻamaʻi viral i le lumanaʻi. O lo'o o'o mai kamupani fa'aola tetele ma sui fou o vaila'au antiviral e fa'afetaui ai le fa'atupula'ia o mana'oga, lea o lo'o lagolagoina le fa'atupulaia o tupe maua mai maketi. Pfizer PFE ma Merck MRK, lea maketi Paxlovid ma molnupiravir, i le faasologa, o loo pulea le COVID-19 antiviral maketi togafitiga i le US Ua faamaonia e le Food and Drug Administration (FDA) Paxlovid ma molnupiravir e avea ma vailaau fou o vailaau antiviral mo le le falemai COVID- 19 faʻamaʻi ma faʻatagaina i latou mo faʻalavelave faʻafuaseʻi ia Tesema 2021.

OA MEA E AVEA MAI LENEI TUSI:

Increase in COVID-19 cases, as well as continuous availability of a robust product pipeline of antiviral drugs, are expected to support market growth revenue during the forecast period.
The Food and Drug Administration (FDA) approved Paxlovid and molnupiravir as new oral antiviral drug options for non-hospitalized COVID-19 infections and authorized them for emergency use in December 2021.
Pfizer PFE and Merck MRK, which market Paxlovid and molnupiravir, respectively, are dominating the COVID-19 antiviral treatment market in the U.